Clinical Trial Update: ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of ASLAN001 in advanced or metastatic cholangiocarcinoma that progressed after at least one prior systemic therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• ASLAN001

Snippet

Sponsor: ASLAN Pharmaceuticals | Conditions: Cholangiocarcinoma | Phase 2 | Status: COMPLETED